Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.
Summary of Non-Consolidated Financial Results
for the Year Ended March 31, 2021
(Based on Japanese GAAP)
May 13, 2021 | ||||||||||||||||||||||
Company name: | RIBOMIC Inc. | |||||||||||||||||||||
Stock exchange listing: | Tokyo | |||||||||||||||||||||
Stock code: | 4591 | URL https://www.ribomic.com/ | ||||||||||||||||||||
Representative: | President and CEO | Yoshikazu Nakamura | ||||||||||||||||||||
Inquiries: | Corporate Officer Finance and Accounting | Shoji Yonebayashi | TEL 03(3440)3745 | |||||||||||||||||||
Department | ||||||||||||||||||||||
Scheduled date of ordinary general meeting of shareholders: | June 29, 2021 | |||||||||||||||||||||
Scheduled date to file Securities Report: | June 30, 2021 | |||||||||||||||||||||
Scheduled date to commence dividend payments: | - | |||||||||||||||||||||
Preparation of supplementary material on financial results: | Yes | |||||||||||||||||||||
Holding of financial results meeting: | Yes | (for institutional investors and analysts) | ||||||||||||||||||||
(Amounts less than one million yen are rounded down) | ||||||||||||||||||||||
1. Non-consolidated financial results for the year ended March 31, 2021 (from April 1, 2020 to March 31, 2021) | ||||||||||||||||||||||
(1) Non-consolidated operating results | Percentages indicate year-on-year changes | |||||||||||||||||||||
Operating revenues | Operating income | Ordinary income | Profit | |||||||||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | |||||||||||||||
Year ended March 31, 2021 | 91 | (24.2) | (1,239) | - | (1,184) | - | (1,187) | - | ||||||||||||||
Year ended March 31, 2020 | 121 | - | (914) | - | (853) | - | (855) | - | ||||||||||||||
Earnings per share | Diluted earnings per | Profit/equity | Ordinary | Operating | ||||||||||||||||||
share | income/total assets | income/net revenues | ||||||||||||||||||||
Yen | Yen | % | % | % | ||||||||||||||||||
Year ended March 31, 2021 | (46.17) | - | (29.1) | (28.2) | - | |||||||||||||||||
Year ended March 31, 2020 | (53.62) | - | (46.9) | (35.3) | (753.5) | |||||||||||||||||
Reference: Share of income of investments accounted for using the equity method. | ||||||||||||||||||||||
Year ended March 31, 2021 | ¥ - Million | |||||||||||||||||||||
Year ended March 31, 2020 | ¥ - Million | |||||||||||||||||||||
Note: Diluted earnings per share is not shown because a net loss per share was incurred even though dilutive common shares exist. | ||||||||||||||||||||||
(2) Non-consolidated financial position | ||||||||||||||||||||||
Total assets | Net assets | Equity ratio | Net assets per share | |||||||||||||||||||
Millions of yen | Millions of yen | % | Yen | |||||||||||||||||||
As of March 31, 2021 | 6,119 | 6,002 | 98.1 | 215.04 | ||||||||||||||||||
As of March 31, 2020 | 2,269 | 2,180 | 95.3 | 123.27 | ||||||||||||||||||
Reference: Equity | As of March 31, 2021 | ¥6,001 | Million | |||||||||||||||||||
As of March 31, 2020 | ¥2,164 Million | |||||||||||||||||||||
(3) Non-consolidated cash flows | ||||||||||||||||||||||
Cash flows from | Cash flows from | Cash flows from | Cash and cash equivalents | |||||||||||||||||||
operating activities | investing activities | financing activities | at end of period | |||||||||||||||||||
Millions of yen | Millions of yen | Millions of yen | Millions of yen | |||||||||||||||||||
Year ended March 31, 2021 | (1,149) | (1,699) | 4,988 | 3,338 | ||||||||||||||||||
Year ended March 31, 2020 | (902) | 553 | 536 | 1,199 | ||||||||||||||||||
1
2. Cash dividends
Annual dividends per share | Total cash | Dividend payout | Ratio of dividends | |||||
ratio (Non- | to net assets (Non- | |||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | Total | dividends (Total) | consolidated) | consolidated) | |
Yen | Yen | Yen | Yen | Yen | Millions of yen | % | % | |
Year ended March 31, 2020 | - | 0.00 | - | 0.00 | 0.00 | - | - | - |
Year ended March 31, 2021 | - | 0.00 | - | 0.00 | 0.00 | - | - | - |
Year ending March 31, 2022 | - | 0.00 | - | 0.00 | 0.00 | - | ||
(Forecast) | ||||||||
3. Forecast of non-consolidated financial results for the year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)
Percentages indicate year-on-year changes
Operating revenues | Operating income | Ordinary income | Profit | Earnings per share | |||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | |||
Full year | 80 | (11.9) | (2,495) | - | (2,391) | - | (2,393) | - | (85.75) | ||
Note: The Company only provides full-year forecasts as it manages its performance on an annual basis.
4. Notes
(1) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations: | No |
Changes in accounting policies due to other reasons: | No |
Changes in accounting estimates: | No |
Restatement of prior period financial statements: | No |
(2) Number of issued shares (common shares)
Total number of issued shares at the end of the period (including treasury shares)
As of March 31, 2021 | 27,908,784 | shares | As of March 31, 2020 | 17,555,784 | shares | |
Number of treasury shares at the end of the period | ||||||
As of March 31, 2021 | - shares | As of March 31, 2020 | - shares | |||
Average number of shares during the period | ||||||
Year ended March 31, 2021 | 25,712,891 | shares | Year ended March 31, 2020 | 15,944,883 | shares |
- This financial results report is exempt from the audit procedures.
- Explanation on appropriate use of business forecasts, and other special notes.
1.Business forecasts and other forward-looking statements contained in this report are based on information currently available to the company and on certain assumptions that the company considers to be reasonable, and do not constitute guarantees of future performance. Actual results may differ significantly from these forecasts due to various factors.
- Supplementary materials are disclosed via TDnet and available on the company's website.
- The company plans to hold a financial results meeting for institutional investors and analysts on May 14, 2021.
2
Non-consolidated financial statements
Non-consolidated balance sheets
(Thousands of yen) | |||
As of March 31, 2020 | As of March 31, 2021 | ||
Assets | |||
Current assets | |||
Cash and deposits | 1,601,728 | 3,338,038 | |
Accounts receivable - trade | 108,830 | - | |
Securities | 399,994 | 2,500,000 | |
Supplies | 6,364 | 3,038 | |
Advance payments - trade | 2,390 | 153,984 | |
Prepaid expenses | 18,764 | 18,358 | |
Accounts receivable - other | 1,831 | 201 | |
Consumption taxes receivable | 34,028 | 35,894 | |
Other | 1,661 | 823 | |
Total current assets | 2,175,594 | 6,050,339 | |
Non-current assets | |||
Property, plant and equipment | |||
Buildings | 22,555 | 22,851 | |
Accumulated depreciation | (14,415) | (15,220) | |
Buildings, net | 8,139 | 7,631 | |
Tools, furniture and fixtures | 270,053 | 268,436 | |
Accumulated depreciation | (222,380) | (245,336) | |
Tools, furniture and fixtures, net | 47,673 | 23,099 | |
Total property, plant and equipment | 55,812 | 30,731 | |
Intangible assets | |||
Software | 1,626 | 151 | |
Total intangible assets | 1,626 | 151 | |
Investments and other assets | |||
Shares of subsidiaries and associates | 22,552 | 22,552 | |
Leasehold deposits | 13,560 | 12,800 | |
Long-term prepaid expenses | 591 | 3,085 | |
Total investments and other assets | 36,704 | 38,438 | |
Total non-current assets | 94,143 | 69,320 | |
Total assets | 2,269,737 | 6,119,660 | |
Liabilities | |||
Current liabilities | |||
Accounts payable - other | 24,230 | 43,357 | |
Accrued expenses | 10,202 | 11,137 | |
Income taxes payable | 28,038 | 39,537 | |
Advances received | 6,875 | 3,666 | |
Deposits received | 6,442 | 6,262 | |
Other | 13,000 | 13,000 | |
Total current liabilities | 88,788 | 116,960 | |
Total liabilities | 88,788 | 116,960 |
3
(Thousands of yen) | |||
As of March 31, 2020 | As of March 31, 2021 | ||
Net assets | |||
Shareholders' equity | |||
Capital Stock | 4,029,956 | 6,542,185 | |
Capital surplus | |||
Legal capital surplus | 4,002,956 | 6,515,185 | |
Total capital surpluses | 4,002,956 | 6,515,185 | |
Retained earnings | |||
Other retained earnings | |||
Retained earnings brought forward | (5,868,737) | (7,055,932) | |
Total retained earnings | (5,868,737) | (7,055,932) | |
Total shareholders' equity | 2,164,174 | 6,001,438 | |
Share acquisition rights | 16,773 | 1,261 | |
Total net assets | 2,180,948 | 6,002,699 | |
Total liabilities and net assets | 2,269,737 | 6,119,660 |
4
Non-consolidated statements of income
(Thousands of yen) | |||
Fiscal year ended | Fiscal year ended | ||
March 31, 2020 | March 31, 2021 | ||
Operating revenues | 121,385 | 91,963 | |
Operating expenses | |||
Research and development expenses | 673,605 | 957,605 | |
Selling, general and administrative expenses | 362,360 | 374,000 | |
Total operating expenses | 1,035,965 | 1,331,606 | |
Operating loss | (914,580) | (1,239,643) | |
Non-operating income | |||
Interest income | 993 | 248 | |
Subsidy income | 74,855 | 82,727 | |
Other | 1,203 | 1,221 | |
Total non-operating income | 77,053 | 84,196 | |
Non-operating expenses | |||
Share issuance cost | 14,305 | 20,414 | |
Loss on redemption of bonds | 2,000 | - | |
Foreign exchange losses | - | 9,137 | |
Total non-operating expenses | 16,305 | 29,552 | |
Ordinary loss | (853,832) | (1,184,998) | |
Extraordinary losses | |||
Loss on retirement of non-current assets | - | 985 | |
Total extraordinary losses | - | 985 | |
Loss before income taxes | (853,832) | (1,185,984) | |
Income taxes - current | 1,210 | 1,210 | |
Total income taxes | 1,210 | 1,210 | |
Loss | (855,042) | (1,187,194) |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Ribomic Inc. published this content on 25 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2021 08:46:02 UTC.